Trials / Active Not Recruiting
Active Not RecruitingNCT06226896
Effects of Dapagliflozin on Progression of Alport Syndrome
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 222 (actual)
- Sponsor
- Nanjing University School of Medicine · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Recently, a series of large clinical trials have confirmed the cardio-renal protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors. but few patients with hereditary nephritis were included in these studies. This study is to evaluate the effects of dapagliflozin on slowing kidney disease progression in patients with Alport syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapagliflozin 10mg Tab | Dapagliflozin 10mg daily plus RAS inhibitor |
Timeline
- Start date
- 2023-11-15
- Primary completion
- 2026-06-30
- Completion
- 2026-09-30
- First posted
- 2024-01-26
- Last updated
- 2024-09-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06226896. Inclusion in this directory is not an endorsement.